Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Quinolones/administration & dosage"'
Autor:
Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor
Publikováno v:
Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e25362cf07bd88d1d3728962d9a50
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK
Autor:
Daniel Peckham, Paul Whitaker, Anil Mehta, Sinisa Savic, Michael F. McDermott, T. Scambler, J. Holbrook, Christine Etherington, Ian Clifton, Heledd H. Jarosz-Griffiths, Samuel Lara-Reyna, Giulia Spoletini, C. Wong, Fabio Martinon
Publikováno v:
eLife
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
eLife, Vol 9 (2020)
eLife, vol. 9, pp. e54556
Previously, we showed that serum and monocytes from patients with CF exhibit an enhanced NLRP3-inflammasome signature with increased IL-18, IL-1β, caspase-1 activity and ASC speck release (Scambler et al. eLife 2019). Here we show that CFTR modulato
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56c3b19820b0ec649de1acb486b5ee6
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
https://eprints.whiterose.ac.uk/158253/7/elife-54556-v2.pdf
Autor:
VX17-445-103 Trial Group
Background: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators correct the basic defect caused by CFTR mutations. Improvements in health outcomes have been achieved with the combination of a CFTR corrector and potentiator in people
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_____10691::89138b60eee52c990cd8474204258594
https://dspace.library.uu.nl/handle/1874/391989
https://dspace.library.uu.nl/handle/1874/391989
Publikováno v:
Lehmann, S, Ringbæk, T, Løkke, A, Grote, L, Hedner, J & Lindberg, E 2019, ' A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD : the DuoSleep study ', International Journal of Chronic Obstructive Pulmonary Disease, vol. 14, pp. 199-210 . https://doi.org/10.2147/COPD.S184127
Lehmann, S, Ringbaek, T, Lokke, A, Grote, L, Hedner, J & Lindberg, E 2019, ' A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD : the DuoSleep study ', International Journal of Chronic Obstructive Pulmonary Disease, vol. 14, pp. 199-210 . https://doi.org/10.2147/COPD.S184127
The International Journal of Chronic Obstructive Pulmonary Disease
International Journal of Chronic Obstructive Pulmonary Disease
Lehmann, S, Ringbaek, T, Lokke, A, Grote, L, Hedner, J & Lindberg, E 2019, ' A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD : the DuoSleep study ', International Journal of Chronic Obstructive Pulmonary Disease, vol. 14, pp. 199-210 . https://doi.org/10.2147/COPD.S184127
The International Journal of Chronic Obstructive Pulmonary Disease
International Journal of Chronic Obstructive Pulmonary Disease
Sverre Lehmann,1,2 Thomas Ringbæk,3 Anders Løkke,4 Ludger Grote,5 Jan Hedner,6 Eva Lindberg7 1Department of Thoracic Medicine, Norwegian Competence Center for Sleep Disorders, Haukeland University Hospital, Bergen, Norway; 2Section of Thoracic Medi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c48d2846d648e8f2dd6491368b8f863
https://curis.ku.dk/ws/files/235001089/copd_184127_a_randomized_trial_to_determine_the_impact_of_indacaterol_gl_010819.pdf
https://curis.ku.dk/ws/files/235001089/copd_184127_a_randomized_trial_to_determine_the_impact_of_indacaterol_gl_010819.pdf
Autor:
Alexander Turk, Thomas Geiser, Andreas Clemens, Andrea Azzola, Joerg Salomon, Thomas Sigrist, Martin Brutsche, Jean-Georges Frey, Guido Domenighetti, Konstantinos Kostikas, Daiana Stolz, Corinne Wild, Jean-William Fitting, Ulrich Schmidt
Publikováno v:
Salomon, Joerg; Stolz, Daiana; Domenighetti, Guido; Frey, Jean-Georges; Turk, Alexander J; Azzola, Andrea; Sigrist, Thomas; Fitting, Jean-William; Schmidt, Ulrich; Geiser, Thomas; Wild, Corinne; Kostikas, Konstantinos; Clemens, Andreas; Brutsche, Martin (2017). Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD-a randomised controlled study. Respiratory research, 18(1), p. 13. BioMed Central 10.1186/s12931-016-0498-1
Respiratory Research
Respiratory research, vol. 18, no. 1, pp. 13
Respiratory Research
Respiratory research, vol. 18, no. 1, pp. 13
Background Dual bronchodilator therapy is recommended for symptomatic patients with chronic obstructive pulmonary disease (COPD). There are limited data on effects of a combination of two long-acting bronchodilators on lung function including body pl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6922429012900f149e67ba56981220dc
https://boris.unibe.ch/106601/1/s12931-016-0498-1.pdf
https://boris.unibe.ch/106601/1/s12931-016-0498-1.pdf
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.